EDG3抗体;EDG3 Antibody—艾普蒂

+ +

•  

   

     Western blot analysis of EDG3 expression in HepG2 cell lysate.    

  
  

The EDG3 antibody targets the Sphingosine-1-phosphate receptor 3 (S1PR3), a G protein-coupled receptor (GPCR) encoded by the *S1PR3* gene. Originally classified under the endothelial differentiation gene (EDG) family, S1PR3 binds sphingosine-1-phosphate (S1P), a bioactive lipid regulating cell proliferation, migration, and survival. S1PR3 is implicated in diverse physiological processes, including vascular development, immune response, and angiogenesis, and is linked to pathologies such as cancer, inflammation, and cardiovascular diseases.

EDG3 antibodies are critical tools for studying S1PR3 expression, localization, and function. They enable detection of receptor levels in tissues or cell lines via techniques like Western blot, immunohistochemistry, or flow cytometry. Researchers use these antibodies to explore S1PR3's role in S1P-mediated signaling pathways, such as PI3K/Akt and MAPK, and its crosstalk with other receptors. In disease models, EDG3 antibodies help assess S1PR3's involvement in tumor progression, immune modulation, or endothelial dysfunction.

Therapeutic applications are also emerging, as S1PR3 is a potential target for drugs addressing autoimmune disorders or cancer. Antibodies may serve as diagnostic biomarkers or therapeutic agents, either alone or conjugated to drugs. Both monoclonal and polyclonal EDG3 antibodies are available, with specificity and affinity varying based on epitope recognition. Validation across applications remains essential to ensure reliability in experimental and clinical contexts.